Ariana D. Majer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ariana D. Majer has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Angela Estell
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
82 shared publications - Christopher A. Natale
Linnaeus Therapeutics, Haddonfield, New Jersey
82 shared publications - Inyoung Lee
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
82 shared publications - J. Kevin Foskett
University of Pennsylvania
82 shared publications - Jillian Weissenrieder
Department of Physiology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
82 shared publications - Martin Carroll
Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
82 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential
Supplementary Table S2. Individual PDGO DNA sequencing data.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential
Supplementary Table S2. Individual PDGO DNA sequencing data.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential
Supplementary Table S1. Baseline characteristics of the study cohort.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential
Supplementary Table S1. Baseline characteristics of the study cohort.
- 22 April 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- p. OF1-OF12
Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential
An accumulating body of evidence suggests that carriers of a pathogenic germline variant (PGV) in BRCA1 or BRCA2 have an increased gastric cancer risk. BRCA1 and BRCA2 are tumor suppressor genes involved in promoting homologous recombination to repair double-stranded DNA breaks. The aim of this investigation was to identify differences within the gastric epithelium and in patient-derived gastric organoids (PDGO) between BRCA1 and BRCA2 carriers and noncarriers to determine if evidence of early gastric carcinogenesis exists among these carriers. First, using gastric epithelial biopsies, BRCA2 carriers were found to harbor higher expression of the proliferative marker Ki-67 within the antral gastric epithelium, and strikingly, biopsies from both BRCA1 and BRCA2 carriers displayed a marked increase in double-stranded DNA damage. These results were further explored using PDGOs, in which a growth advantage was observed for both BRCA1 and BRCA2 PDGOs compared with noncarrier PDGOs. Furthermore, both BRCA1 and BRCA2 PDGOs displayed a more pronounced enhancement of Ki-67 expression as well as increased double-stranded DNA damage compared with noncarrier PDGOs. Importantly, none of the PDGOs showed signs of BRCA1 or BRCA2 loss of heterozygosity, potentially indicating a haploinsufficient phenotype. Taken together, these novel findings suggest that haploinsufficiency in BRCA1 and BRCA2 carriers may lead to DNA damage in the gastric epithelium, which may serve as an early event contributing to gastric cancer development. Implications: The elevated risk of gastric cancer for BRCA1 and BRCA2 PGV carriers may be due to haploinsufficiency, which warrants further investigation into mechanisms of BRCA1- and BRCA2-associated gastric cancer.
- 22 April 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- p. OF1-OF12
Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential
An accumulating body of evidence suggests that carriers of a pathogenic germline variant (PGV) in BRCA1 or BRCA2 have an increased gastric cancer risk. BRCA1 and BRCA2 are tumor suppressor genes involved in promoting homologous recombination to repair double-stranded DNA breaks. The aim of this investigation was to identify differences within the gastric epithelium and in patient-derived gastric organoids (PDGO) between BRCA1 and BRCA2 carriers and noncarriers to determine if evidence of early gastric carcinogenesis exists among these carriers. First, using gastric epithelial biopsies, BRCA2 carriers were found to harbor higher expression of the proliferative marker Ki-67 within the antral gastric epithelium, and strikingly, biopsies from both BRCA1 and BRCA2 carriers displayed a marked increase in double-stranded DNA damage. These results were further explored using PDGOs, in which a growth advantage was observed for both BRCA1 and BRCA2 PDGOs compared with noncarrier PDGOs. Furthermore, both BRCA1 and BRCA2 PDGOs displayed a more pronounced enhancement of Ki-67 expression as well as increased double-stranded DNA damage compared with noncarrier PDGOs. Importantly, none of the PDGOs showed signs of BRCA1 or BRCA2 loss of heterozygosity, potentially indicating a haploinsufficient phenotype. Taken together, these novel findings suggest that haploinsufficiency in BRCA1 and BRCA2 carriers may lead to DNA damage in the gastric epithelium, which may serve as an early event contributing to gastric cancer development. Implications: The elevated risk of gastric cancer for BRCA1 and BRCA2 PGV carriers may be due to haploinsufficiency, which warrants further investigation into mechanisms of BRCA1- and BRCA2-associated gastric cancer.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S3. GPER expression grossly does not correlate with AML outcome and mutation status (A) GPER expression stratified by ELN2017. (B) GPER expression stratified by FLT3-ITD mutation status. (C) GPER expression stratified by different AML fusion proteins. All data were acquired from the BEAT-AML dataset. P-values were calculated via one-way ANOVA multiple comparisons (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001).
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S3. GPER expression grossly does not correlate with AML outcome and mutation status (A) GPER expression stratified by ELN2017. (B) GPER expression stratified by FLT3-ITD mutation status. (C) GPER expression stratified by different AML fusion proteins. All data were acquired from the BEAT-AML dataset. P-values were calculated via one-way ANOVA multiple comparisons (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001).
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 does not inhibit AML in systemic in vivo model (A) Proliferation assay of luciferase-expressing MV4-11 (MV4-11-Luc) cells. Cells were incubated for 72 hours and were counted with trypan blue dye. 5 replicates were used for experiment. P-values were calculated via pairwise t-tests (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001). (B) Systemic in vivo experiment done with MV4-11-Luc. Male NSG mice were used for the experiment. Mice were treated with vehicle or LNS8801 daily through oral gavage. 3 animals were used per condition.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 does not inhibit AML in systemic in vivo model (A) Proliferation assay of luciferase-expressing MV4-11 (MV4-11-Luc) cells. Cells were incubated for 72 hours and were counted with trypan blue dye. 5 replicates were used for experiment. P-values were calculated via pairwise t-tests (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001). (B) Systemic in vivo experiment done with MV4-11-Luc. Male NSG mice were used for the experiment. Mice were treated with vehicle or LNS8801 daily through oral gavage. 3 animals were used per condition.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S9. Mcl-1 is not responsible for LNS8801-induced death in AML (A) Proliferation assay dose curve of AML cells treated with the Mcl-1 specific inhibitor S63845. Cells were treated with drug for 72 hours. 6 replicates were used per dose. (B) Western blot of U937 cells overexpressing Mcl-1, treated with 250nM LNS8801 for 24 hours. (C) Annexin V flow analysis of U937 cells overexpressing Mcl-1. Cells were treated for 72 hours. 3 replicates were used per condition. Two-way ANOVA was used for statistical analysis for Annexin V+ flow cytometry comparing wild-type and Mcl-1 overexpressing U937 cells.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Supplementary Figure S9. Mcl-1 is not responsible for LNS8801-induced death in AML (A) Proliferation assay dose curve of AML cells treated with the Mcl-1 specific inhibitor S63845. Cells were treated with drug for 72 hours. 6 replicates were used per dose. (B) Western blot of U937 cells overexpressing Mcl-1, treated with 250nM LNS8801 for 24 hours. (C) Annexin V flow analysis of U937 cells overexpressing Mcl-1. Cells were treated for 72 hours. 3 replicates were used per condition. Two-way ANOVA was used for statistical analysis for Annexin V+ flow cytometry comparing wild-type and Mcl-1 overexpressing U937 cells.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
(A and C) Representative DCF histograms of (A) U937 and (C) MOLM14 cells treated with 250nM LNS8812 or 250nM LNS8801 at indicated time points. (B and D) Summary graph of median fluorescence intensity (MFI) of (B) U937 and (D) MOLM14 cells treated with 250nM LNS8812 or 250nM LNS8801. 3 replicates were analyzed per condition. Statistical analysis was done via one-way ANOVA with multiple comparisons was used for panels B and D (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001).
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
(A and C) Representative DCF histograms of (A) U937 and (C) MOLM14 cells treated with 250nM LNS8812 or 250nM LNS8801 at indicated time points. (B and D) Summary graph of median fluorescence intensity (MFI) of (B) U937 and (D) MOLM14 cells treated with 250nM LNS8812 or 250nM LNS8801. 3 replicates were analyzed per condition. Statistical analysis was done via one-way ANOVA with multiple comparisons was used for panels B and D (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001).
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Data from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Despite recent therapeutic advances, the 5-year survival rate for adults with acute myeloid leukemia (AML) is poor and standard-of-care chemotherapy is associated with significant toxicity, highlighting the need for new therapeutic approaches. Recent work from our group and others established that the G protein-coupled estrogen receptor (GPER) is tumor suppressive in melanoma and other solid tumors. We performed a preliminary screen of human cancer cell lines from multiple malignancies and found that LNS8801, a synthetic pharmacologic agonist of GPER currently in early phase clinical trials, promoted apoptosis in human AML cells. Using human AML cell lines and primary cells, we show that LNS8801 inhibits human AML in preclinical in vitro models, while not affecting normal mononuclear cells. Although GPER is broadly expressed in normal and malignant myeloid cells, this cancer-specific LNS8801-induced inhibition appeared to be independent of GPER signaling. LNS8801 induced AML cell death primarily through a caspase-dependent apoptosis pathway. This was independent of secreted classical death receptor ligands, and instead required induction of reactive oxygen species (ROS) and activation of endoplasmic reticulum (ER) stress response pathways including IRE1α. These studies demonstrate a novel activity of LNS8801 in AML cells and show that targeting ER stress with LNS8801 may be a useful therapeutic approach for AML.Significance:Previous work demonstrated that LNS8801 inhibits cancer via GPER activation, especially in solid tumors. Here we show that LNS8801 inhibits AML via GPER-independent mechanisms that include ROS induction and ER activation.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
Despite recent therapeutic advances, the 5-year survival rate for adults with acute myeloid leukemia (AML) is poor and standard-of-care chemotherapy is associated with significant toxicity, highlighting the need for new therapeutic approaches. Recent work from our group and others established that the G protein-coupled estrogen receptor (GPER) is tumor suppressive in melanoma and other solid tumors. We performed a preliminary screen of human cancer cell lines from multiple malignancies and found that LNS8801, a synthetic pharmacologic agonist of GPER currently in early phase clinical trials, promoted apoptosis in human AML cells. Using human AML cell lines and primary cells, we show that LNS8801 inhibits human AML in preclinical in vitro models, while not affecting normal mononuclear cells. Although GPER is broadly expressed in normal and malignant myeloid cells, this cancer-specific LNS8801-induced inhibition appeared to be independent of GPER signaling. LNS8801 induced AML cell death primarily through a caspase-dependent apoptosis pathway. This was independent of secreted classical death receptor ligands, and instead required induction of reactive oxygen species (ROS) and activation of endoplasmic reticulum (ER) stress response pathways including IRE1α. These studies demonstrate a novel activity of LNS8801 in AML cells and show that targeting ER stress with LNS8801 may be a useful therapeutic approach for AML.Significance:Previous work demonstrated that LNS8801 inhibits cancer via GPER activation, especially in solid tumors. Here we show that LNS8801 inhibits AML via GPER-independent mechanisms that include ROS induction and ER activation.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 does not inhibit AML in systemic in vivo model (A) Proliferation assay of luciferase-expressing MV4-11 (MV4-11-Luc) cells. Cells were incubated for 72 hours and were counted with trypan blue dye. 5 replicates were used for experiment. P-values were calculated via pairwise t-tests (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001). (B) Systemic in vivo experiment done with MV4-11-Luc. Male NSG mice were used for the experiment. Mice were treated with vehicle or LNS8801 daily through oral gavage. 3 animals were used per condition.
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 does not inhibit AML in systemic in vivo model (A) Proliferation assay of luciferase-expressing MV4-11 (MV4-11-Luc) cells. Cells were incubated for 72 hours and were counted with trypan blue dye. 5 replicates were used for experiment. P-values were calculated via pairwise t-tests (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001). (B) Systemic in vivo experiment done with MV4-11-Luc. Male NSG mice were used for the experiment. Mice were treated with vehicle or LNS8801 daily through oral gavage. 3 animals were used per condition.
- Open Access
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 inhibits AML colony formation. A, Colony formation assay of primary AML cells in either DMSO or 250 nmol/L LNS8801. Three replicates were used per condition. B, Colony formation of normal mononuclear cells in either DMSO or 250 nmol/L LNS8801. Three replicates were used per condition. CFU: Colony forming units. BFU: Blast forming units. CFU-G: CFU-granulocytes. CFU-M: CFU-monocytes. CFU-GM: CFU-granulocyte/monocyte. BFU-E: BFU-Erythrocytes. CFU-GEMM: CFU-granulocyte/erythrocyte/monocyte/megakaryocyte. CFU-E: CFU-erythrocyte P values were calculated using t tests (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001).
- 18 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway
LNS8801 inhibits AML colony formation. A, Colony formation assay of primary AML cells in either DMSO or 250 nmol/L LNS8801. Three replicates were used per condition. B, Colony formation of normal mononuclear cells in either DMSO or 250 nmol/L LNS8801. Three replicates were used per condition. CFU: Colony forming units. BFU: Blast forming units. CFU-G: CFU-granulocytes. CFU-M: CFU-monocytes. CFU-GM: CFU-granulocyte/monocyte. BFU-E: BFU-Erythrocytes. CFU-GEMM: CFU-granulocyte/erythrocyte/monocyte/megakaryocyte. CFU-E: CFU-erythrocyte P values were calculated using t tests (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001).